Viking Therapeutics GLP-1 obesity drug shows 22% weight loss
Viking Therapeutics said its experimental GLP-1 obesity drug helped patients lose 22% of body weight after 33 weeks of weekly treatment in a maintenance study.
Viking Therapeutics NASDAQ:VKTX said on Tuesday its experimental GLP-1 obesity drug helped patients lose 22% of their body weight after 33 weeks of weekly treatment in a maintenance study.